Preferred test to follow-up presumptive results. For general screening, THC (Cannabinoids), Urine Screen with Reflex to Quantitation (2012270) is preferred.
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Transfer 1 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Specimens exposed to repeated freeze/thaw cycles.
Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 Month
Effective November 18, 2019
|Drugs Covered||Cutoff Concentrations|
Methodology: Liquid Chromatography-Tandem Mass Spectrometry
Positive cutoff: 15 ng/mL
For medical purposes only; not valid for forensic use.
The drug analyte detected in this assay, 9-carboxy THC, is a metabolite of delta-9-tetrahydrocannabinol (THC). Detection of 9-carboxy THC suggests use of, or exposure to, a product containing THC. This test cannot distinguish between prescribed or non-prescribed forms of THC, nor can it distinguish between active or passive use. The 9-carboxy THC metabolite can be detected in urine for several weeks. Normalization of results to creatinine concentration can help document elimination or suggest recent use, when specimens are collected at least one week apart.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Compare to Pain Management, Marijuana Metabolite, Quantitative, with medMATCH, Urine; Pain Management, Marijuana Metabolite, with Confirmation with medMATCH, Urine.
80349 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
|0090369||11-Nor-9-carboxy-THC, Urn, Quant||3436-3|
- Pain Management